Blood and Lymphatic Cancer : Targets and Therapy

The evaluation and optimal use of rituximab in lymphoid malignancies

Author(s): Robak T | Robak P | Smolewski P
Volume: 2012
Issue: default
Year: 2012

Trends in the treatment of cutaneous T-cell lymphoma – critical evaluation and perspectives on vorinostat

Author(s): Rangwala S | Duvic M | Zhang CL
Volume: 2012
Issue: default
Year: 2012

Advances in the diagnosis and management of lymphoma

Author(s): Word ZH | Matasar MJ
Volume: 2012
Issue: default
Year: 2012

Emerging treatment approaches in acute lymphoblastic and acute myeloid leukemias

Author(s): Thomas X
Volume: 2012
Issue: default
Year: 2012

Treatment strategies for patients with diffuse large B-cell lymphoma: past, present, and future

Author(s): Sinha R | Nastoupil LJ | Flowers CR
Volume: 2012
Issue: default
Year: 2012

First-line therapy of chronic myeloid leukemia – focus on dasatinib

Author(s): Amrein PC
Volume: 2012
Issue: default
Year: 2012

Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma

Author(s): Mayes S | Gibb A | Illidge T
Volume: 2012
Issue: default
Year: 2012

Peripheral T cell lymphoma: clinical utility of romidepsin

Author(s): Zain J | Sawey K
Volume: 2012
Issue: default
Year: 2012

Role of L-asparaginase in acute lymphoblastic leukemia: focus on adult patients

Author(s): Rytting ME
Volume: 2012
Issue: default
Year: 2012

Recent developments in myelofibrosis

Author(s): Tibes R | Bogenberger JM | Mesa RA
Volume: 2012
Issue: default
Year: 2012

Pharmacology and clinical potential of oblimersen sodium in the treatment of chronic lymphocytic leukemia

Author(s): Borthakur G | O'Brien S
Volume: 2012
Issue: default
Year: 2012

A new era in blood and lymphatic cancer biology and therapy

Author(s): David Dingli
Volume: 2011
Issue: default
Year: 2011

Mantle cell leukemia as a cause of leukostasis

Author(s): Smith D | Cable C | Chisholm C | Linz W | Koss W | Dobin S | Rappaport E
Volume: 2011
Issue: default
Year: 2011

Leptomeningeal myelomatosis in previously treated high-risk kappa light chain multiple myeloma: case report and literature review

Author(s): Ohanian M | Alaly J | Samuel S | Cable C | Halka K
Volume: 2011
Issue: default
Year: 2011

mTOR inhibitor in the treatment of Hodgkin’s lymphoma: a case report

Author(s): Ibeas P | Cantos B | Provencio M.
Volume: 2011
Issue: default
Year: 2011

Reduced intensity treatment in early-stage Hodgkin’s lymphoma

Author(s): Prodduturi P | Armitage JO
Volume: 2011
Issue: default
Year: 2011

Therapeutic developments in acute lymphoblastic leukemia

Author(s): MacKenzie A | Kasner M
Volume: 2012
Issue: default
Year: 2012

Novel conditioning regimens for bone marrow transplantation

Author(s): Shi M | Li M | Ikehara S
Volume: 2013
Issue: default
Year: 2013

Daratumumab improves the anti-myeloma effect of newly emerging multidrug therapies

Author(s): Gopalakrishnan S | Tan D
Volume: 2013
Issue: default
Year: 2013

MicroRNA dysregulation in B-cell non-Hodgkin lymphoma

Author(s): Lim EL | Marra MA
Volume: 2013
Issue: default
Year: 2013

Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma

Author(s): Gupta VA | Nooka AK | Lonial S | Boise LH
Volume: 2013
Issue: default
Year: 2013

Emerging targets in human lymphoma: targeting the MYD88 mutation

Author(s): Wang JQ | Jeelall YS | Horikawa K
Volume: 2013
Issue: default
Year: 2013